Waldenström macroglobulinaemia is an indolent B-cell lymphoma with clearly defined
criteria for diagnosis, initiation of therapy, and response, which was established by …

Background Biologics are used for the treatment of rheumatoid arthritis and many other
conditions. While the efficacy of biologics has been established, there is uncertainty …

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for
which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy …

Purpose We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in
patients with symptomatic, untreated Waldenström macroglobulinemia (WM). Patients and …

In this phase 2 multicenter trial, we evaluated the activity of bortezomib, dexamethasone,
and rituximab (BDR) combination in previously untreated symptomatic patients with …

The advent of biologic agents has provided a more specific and targeted approach to the
treatment of various hematological malignancies and other autoimmune disorders. Such …

Importance Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic
lymphoma, has witnessed several practice-altering advances in recent years. With …

Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

Waldenström macroglobulinemia (WM) is a distinct B-cell disorder resulting from the
accumulation, predominantly in the bone marrow, of clonally related IgM-secreting …

Waldenström macroglobulinaemia (WM) is a rare and incurable lymphoma. Given that the
survival of WM patients can be prolonged, our objective was to describe trends in overall …